Skip to content

Study to evaluate the comparative efficacy of Navak Guggulu and Triphala Guggulu in the Management of Sthaulya (Obesity) in Adolescent

A Randomized Clinical Study to Evaluate the Comparative Efficacy of Navak Guggulu and Triphala Guggulu in the Management of Sthaulya (Obesity) in Adolescent

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/05/033598
Enrollment
100
Registered
2021-05-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E663- Overweight

Interventions

Intervention1: Navak Guggulu: 500mg, two tablets twice a day with Luke warm water orally for 12 weeks Control Intervention1: Triphala Guggulu: 500mg, two tablets twice a day with Luke warm water orall

Sponsors

Guru Ravidas Ayurved University Hoshiarpur Punjab
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Individuals of both genders between age group of 11 to 17 years. 2) Individuals having BMI >23 3) Individuals having classical sign and symptoms of Sthaulya like Chala Udara, Stana, Sphika (Visible Movement in Hip-Abdomen-Breast), Durbalata (weakness), Atikshudha (Excess Hunger), Atitrishna (Excess Thirst), Angagaurava (heaviness in body) etc. 4) Individuals who are willing and able to participate for 12 weeks of duration.

Exclusion criteria

Exclusion criteria: 1. Individuals below 11 year and above 17 years of age. 2. Subjects receiving drugs like steroids and anti depressants etc. 3. Subjects having obesity due to endocrinal disorders like hypothyroidism etc. 4. Subjects with other co-morbid conditions like depression, diabetes mellitus etc. 5. Subjects with concurrent Hepatic Dysfunction (defined as AST and/or ALT > 3 times of the upper normal limit) or Renal dysfunction (defined as S. Creatinine >1.2 mg/dl) 6. Subjects suffering from major systemic illness necessitating long term drug treatment (R.A, PTB, malignancy etc.) 7. Already known hypersensitivity to interventional drug. 8. Subjects not willing for trial. 9. Subjects who have participated in any clinical trial during past 6 months. 10. Any other condition which the Investigator thinks may compromise the safety of the subject.

Design outcomes

Primary

MeasureTime frame
Changes in BMI from baseline to 12 week.Timepoint: 12 weeks

Secondary

MeasureTime frame
Changes in body weight from baseline to 12 week. .â?¢ Changes in body fat percentage and visceral body fat from baseline to 12 week. â?¢Changes in Waist-Hip Ratio from baseline to 12 week. â?¢Changes in Skin Fold Thickness from baseline to 12 week. Timepoint: 12 week

Countries

India

Contacts

Public ContactDr Minakshi

RGGPGA college Paprola

drminakshi2050@gmail.com09418017565

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026